本次股权激励为附条件的股权激励，具体条件为：（1）2026年12月31日前，舜景医药研发管线至少新 增2个IND获得国家药品监督管理局或美国FDA批准;或（2）舜景医药在研创新药项目SGC001注射液(适 应症为"前壁ST段抬高型心肌梗死")二期临床试验按计划顺利推进，2027年3月31日前，二期临床试验受 试者全部入组完成。 本次股权激励将主要用于舜景医药的核心员工以及公司的部分董事、高管等，具体激励方案将由舜景医 药管理层按照直接授予和预留两部分分别执行；对于本次股权激励已授予部分，若以上两个条件均没有 如期实现，则本次股权激励已授予部分的50%将由舜景医药回购注销，回购价格为出资额加同期银行存 款利率；对于未授予部分，将另行设置考核指标，用于后续股权激励。 格隆汇12月1日丨热景生物(688068.SH)公布，公司拟对北京舜景生物医药技术有限公司（以下简称"舜 景医药"）增资3.71亿元，增资价格为26.5元/注册资本，并以此增资价格受让丽水巧达创业投资合伙企 业(有限合伙)（以下简称"丽水巧达"）持有的舜景医药40万股股权。同时，为建立和完善长效激励机 制，激发舜景医药核心团队和骨干人员的积极性，实现 ...

关于公司对舜景医药增资、受让股权同时舜景 医药实施股权激励暨关联交易的公告 证券代码：688068 证券简称：热景生物 公告编号：2025-084 北京热景生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热 景生物"）拟对北京舜景生物医药技术有限公司（以下简称"舜景医药"）增资 3.71 亿元，增资价格为 26.5 元/注册资本，并以此增资价格受让丽水巧达创业 投资合伙企业(有限合伙)（以下简称"丽水巧达"）持有的舜景医药 40 万股股 权。同时，为建立和完善长效激励机制，激发舜景医药核心团队和骨干人员的积 极性，实现长期利益的绑定，舜景医药拟同步实施股权激励，通过新设股权激励 平台北京舜之业企业管理合伙企业（有限合伙）（暂定名，以下简称"舜之业"， 具体以工商登记为准）对舜景医药进行增资 4,000 万元，增资价格为 10 元/注册 资本。 本次增资、受让股权完成后，公司持有舜景医药的股权比例由 43.1842% 增长至 5 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-085 北京热景生物技术股份有限公司 关于与关联方共同投资尧景基因暨关联交易的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易概述：北京热景生物技术股份有限公司（以下简称"公司"或"热 景生物"）、林长青、北京尧景企业管理中心（有限合伙）（以下简称"尧景合 伙"）拟共同对北京尧景基因技术有限公司（以下简称"尧景基因"）进行增资， 增资方案为热景生物出资 2,400 万元，林长青出资 5,000 万元，尧景合伙出资 600 万元，合计出资 8,000 万元，按照 2 元/注册资本的价格进行增资。本次增 资完成后，尧景基因注册资本由 11,000 万元变更为 15,000 万元，公司持有尧景 基因的股权比例由 40.91%变更为 38.00%。 本次增资方林长青为公司控股股东、实际控制人、董事长兼总经理；增 资方北京尧景企业管理中心（有限合伙）为林长青担任执行事务合伙人、公司董 事柳晓利、许立达及公司副总经理兼董事会秘书石永沾为有限合伙 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688068 证券简称：热景生物 公告编号：2025-086 北京热景生物技术股份有限公司 关于召开2025年第五次临时股东会的通知 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第五次临时股东会 召开日期时间：2025 年 12 月 17 日 14 点 30 分 召开地点：北京市大兴区中关村科技园区大兴生物医药产业基地庆丰西路 55 号公司三层会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 17 日 至2025 年 12 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2025年12月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期 ...

格隆汇12月1日｜热景生物公告，公司、林长青、北京尧景企业管理中心（有限合伙）拟共同对尧景基 因进行增资，增资方案为公司出资2,400万元，林长青先生出资5,000万元，北京尧景企业管理中心（有 限合伙）出资600万元，合计出资8,000万元，按照2元/注册资本的价格进行增资。本次增资完成后，尧 景基因注册资本由11,000万元变更为15,000万元，公司持有尧景基因的股权比例由40.91%变更为 38.00%。本次交易有利于尧景基因的长远发展，有利于提升公司长期投资收益，不会影响公司生产经 营的正常运行，不会对公司的财务状况和经营业绩产生重大影响。 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

Core Viewpoint - The company, as the first IVD listed enterprise on the Sci-Tech Innovation Board, is transitioning from in vitro diagnostics to biopharmaceuticals, aligning with the national bio-manufacturing strategy and focusing on long-term growth through global expansion and innovation in the biopharmaceutical sector [2][4]. Group 1: Industry Trends and Company Strategy - Biomanufacturing is recognized as a strategic emerging industry for the next decade, with biopharmaceuticals being a key battleground due to high technical barriers [4]. - The company's expansion from in vitro diagnostics to biopharmaceuticals is seen as a natural extension of its core competencies in biotechnology, emphasizing the interconnectedness of diagnostic and therapeutic technologies [4][5]. - The company has made significant investments in basic research, resulting in publications in top-tier journals and the establishment of a solid R&D framework [4]. Group 2: Innovation and Product Development - The company adheres to the "uniqueness and firstness" principle in its innovation pipeline, focusing on unmet clinical needs and developing products such as the world's first antibody drug for myocardial infarction [8][10]. - The company has developed advanced technologies in liver cancer early screening, which are widely used in high-risk populations and included in expert consensus guidelines [8]. - The company aims to achieve the goal of "Chinese scientists discovering first, Chinese enterprises transforming first, and Chinese hospitals conducting clinical trials first" in its drug development efforts [8]. Group 3: Global Market Expansion - The company has initiated overseas expansion since 2019, achieving over 600 foreign certifications and establishing a presence in Southeast Asia, South Asia, the Middle East, and Latin America [10]. - The company positions its products as high-quality and cost-effective alternatives to those from developed countries, aiming to provide better healthcare options for developing nations [10]. - The company emphasizes the importance of international certifications and understanding local market needs as key factors for successful overseas operations [10].

Market Overview - The medical device sector experienced a decline of 0.38% on November 26, with Kangwei Century leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Top Performers - Haobor (688656) saw a significant increase of 9.38%, closing at 201.80 with a trading volume of 17,200 lots [1] - Shuoshi Biology (6668889) rose by 4.04%, closing at 69.82 with a trading volume of 21,500 lots [1] - Lexin Medical (300562) increased by 3.88%, closing at 14.20 with a trading volume of 107,400 lots [1] Underperformers - Kangwei Century (688426) fell by 10.78%, closing at 27.80 with a trading volume of 33,000 lots [2] - Boxin Biology (920504) decreased by 5.98%, closing at 22.97 with a trading volume of 8,514 lots [2] - Zhengchuan Co. (603976) dropped by 5.25%, closing at 21.30 with a trading volume of 33,800 lots [2] Capital Flow - The medical device sector saw a net outflow of 371 million yuan from institutional investors, while retail investors contributed a net inflow of 43.54 million yuan [2][3] - The top net inflows from institutional investors were seen in Lexin Medical (300562) with a net outflow of 33.13 million yuan [3] - The highest net inflow from retail investors was in Yuyue Medical (002223) with a net inflow of 24.16 million yuan [3]

（文章来源：证券日报） 证券日报网讯 11月24日晚间，热景生物发布公告称，近日，北京热景生物技术股份有限公司（以下简 称"公司"）获得了由中华人民共和国工业和信息化部（以下简称"工信部"）颁发的国家级专精特新"小 巨人"企业证书，入选工信部第七批国家级专精特新"小巨人"企业。 ...

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]